Natera, Inc. (NTRA)
Stock Price:
$51.04 USD
-0.29 (-0.56%)
Updated Aug 11, 2020 2:51 PM EDT - Market open
Key Info
| Market Cap |
4.08B |
| Revenue (ttm) |
341.63M |
| Net Income (ttm) |
-153.33M |
| Shares Out |
79.72M |
| EPS (ttm) |
-2.01 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$51.04 |
| Previous Close |
$51.33 |
| Change ($) |
-0.29 |
| Change (%) |
-0.56% |
| Day's Open |
51.19 |
| Day's Range |
49.16 - 52.10 |
| Day's Volume |
289,077 |
| 52-Week Range |
16.87 - 56.51 |
More Stats
| Market Cap |
4.08B |
| Enterprise Value |
3.78B |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
79.72M |
| Float |
76.32M |
| EPS (basic) |
-1.99 |
| EPS (diluted) |
-2.01 |
| FCF / Share |
-1.48 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.86M |
| Short Ratio |
7.43 |
| Short % of Float |
8.46% |
| Beta |
1.31 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
11.94 |
| PB Ratio |
14.45 |
| Revenue |
341.63M |
| Operating Income |
-142.44M |
| Net Income |
-153.33M |
| Free Cash Flow |
-117.27M |
| Net Cash |
300.59M |
| Net Cash / Share |
3.76 |
| Gross Margin |
37.13% |
| Operating Margin |
-41.69% |
| Profit Margin |
-44.90% |
| FCF Margin |
-34.33% |
| ROA |
-17.51% |
| ROE |
-77.18% |
| ROIC |
-27.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
5 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$62.33*
(22.12% upside)
Low
60.0
Current: $51.04
High
66.0
Target: 62.33
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 302 | 258 | 210 | 213 | 190 | 159 | 55.17 |
| Revenue Growth | 17.34% | 22.91% | -1.36% | 11.64% | 19.5% | 188.72% | - |
| Gross Profit | 127 | 91.60 | 70.03 | 76.94 | 77.51 | 80.89 | 17.90 |
| Operating Income | -116 | -115 | -135 | -101 | -59.84 | 0.67 | -25.27 |
| Net Income | -125 | -128 | -138 | -100 | -70.28 | -5.15 | -37.11 |
| Shares Outstanding | 69.56 | 57.85 | 53.31 | 51.58 | 26.20 | 4.80 | 3.84 |
| Earnings Per Share | -1.79 | -2.22 | -2.59 | -1.95 | -2.68 | -1.07 | -9.66 |
| Operating Cash Flow | -63.44 | -70.58 | -97.83 | -74.05 | -37.83 | 10.49 | -24.13 |
| Capital Expenditures | -4.97 | -3.88 | -9.87 | -23.14 | -7.39 | -9.94 | -8.25 |
| Free Cash Flow | -68.41 | -74.46 | -108 | -97.19 | -45.22 | 0.55 | -32.38 |
| Cash & Equivalents | 441 | 154 | 119 | 146 | 231 | 87.18 | 31.39 |
| Total Debt | 150 | 124 | 123 | 49.62 | 42.09 | 26.81 | 24.31 |
| Net Cash / Debt | 291 | 30.36 | -4.31 | 96.49 | 188 | 60.36 | 7.09 |
| Assets | 583 | 268 | 215 | 211 | 265 | 124 | 59.72 |
| Liabilities | 304 | 236 | 189 | 104 | 80.48 | 54.35 | 46.03 |
| Book Value | 279 | 32.16 | 25.42 | 106 | 185 | -171 | -172 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Natera, Inc. |
| Country |
United States |
| Employees |
1,039 |
| CEO |
Stephen Chapman |
Stock Information
| Ticker Symbol |
NTRA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: NTRA |
| IPO Date |
July 2, 2015 |
Description
Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Evercord, a cord blood and cord tissue processing and storage service; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. Natera, Inc. has research collaborations with the Institut Jules Bordet and Fox Chase Cancer Center; and a partnership agreement with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays for use by biopharmaceutical and clinical customers. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.